OncoQuest

November 15, 2017November 15, 2017

OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo

News

OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is ... Read more

May 26, 2017

Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports

News

Adding oregovomab to standard chemotherapy significantly increases the time it takes for a newly diagnosed advanced ovarian cancer patient to have their disease progress or die, according to a Phase ... Read more

May 10, 2017May 10, 2017

First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer

News

The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest‘s anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial (NCT03100006), ... Read more